Literature DB >> 21213093

Bone marrow cell injection for chronic myocardial ischemia: the past and the future.

Jan van Ramshorst1, Sander F Rodrigo, Martin J Schalij, Saskia L M A Beeres, Jeroen J Bax, Douwe E Atsma.   

Abstract

Intramyocardial bone marrow cell injection is currently being investigated as a new therapeutic option for the treatment of chronic myocardial ischemia. Experimental studies and early phase clinical trials established a favorable safety profile of this approach and suggested that bone marrow cell injection was associated with clinical and functional improvements. Recently, a randomized, double-blind, placebo-controlled trial demonstrated that intramyocardial bone marrow cell injection was associated with beneficial effects on myocardial perfusion and anginal symptoms. However, the mechanisms by which bone marrow cells may improve myocardial perfusion are only partially understood, and several issues remain to be addressed. This review aims to provide a summary of the current experience with bone marrow cell therapy as a novel treatment option for patients with chronic myocardial ischemia. Therefore, the most frequently used cell types will be reviewed along with the mechanisms through which bone marrow cells may improve myocardial perfusion and function. In addition, possible routes of delivery are compared, and the results of currently available experimental and clinical studies are discussed.

Entities:  

Mesh:

Year:  2011        PMID: 21213093      PMCID: PMC3047688          DOI: 10.1007/s12265-010-9249-8

Source DB:  PubMed          Journal:  J Cardiovasc Transl Res        ISSN: 1937-5387            Impact factor:   4.132


  72 in total

Review 1.  Cells as biologics for cardiac repair in ischaemic heart failure.

Authors:  Jozef Bartunek; Marc Vanderheyden; Jonathan Hill; Andre Terzic
Journal:  Heart       Date:  2010-05       Impact factor: 5.994

2.  CD34-/CD133+/VEGFR-2+ endothelial progenitor cell subpopulation with potent vasoregenerative capacities.

Authors:  Erik B Friedrich; Katrin Walenta; John Scharlau; Georg Nickenig; Nikos Werner
Journal:  Circ Res       Date:  2006-01-26       Impact factor: 17.367

3.  Both cell fusion and transdifferentiation account for the transformation of human peripheral blood CD34-positive cells into cardiomyocytes in vivo.

Authors:  Sui Zhang; Dachun Wang; Zeev Estrov; Sean Raj; James T Willerson; Edward T H Yeh
Journal:  Circulation       Date:  2004-12-13       Impact factor: 29.690

4.  Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair.

Authors:  Caroline Schmidt-Lucke; Lothar Rössig; Stephan Fichtlscherer; Mariuca Vasa; Martina Britten; Ulrike Kämper; Stefanie Dimmeler; Andreas M Zeiher
Journal:  Circulation       Date:  2005-05-31       Impact factor: 29.690

5.  Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction.

Authors:  Volker Schächinger; Sandra Erbs; Albrecht Elsässer; Werner Haberbosch; Rainer Hambrecht; Hans Hölschermann; Jiangtao Yu; Roberto Corti; Detlef G Mathey; Christian W Hamm; Tim Süselbeck; Birgit Assmus; Torsten Tonn; Stefanie Dimmeler; Andreas M Zeiher
Journal:  N Engl J Med       Date:  2006-09-21       Impact factor: 91.245

6.  HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway.

Authors:  S Dimmeler; A Aicher; M Vasa; C Mildner-Rihm; K Adler; M Tiemann; H Rütten; S Fichtlscherer; H Martin; A M Zeiher
Journal:  J Clin Invest       Date:  2001-08       Impact factor: 14.808

7.  Transendocardial delivery of autologous bone marrow enhances collateral perfusion and regional function in pigs with chronic experimental myocardial ischemia.

Authors:  S Fuchs; R Baffour; Y F Zhou; M Shou; A Pierre; F O Tio; N J Weissman; M B Leon; S E Epstein; R Kornowski
Journal:  J Am Coll Cardiol       Date:  2001-05       Impact factor: 24.094

8.  Prospective randomized trial of direct endomyocardial implantation of bone marrow cells for treatment of severe coronary artery diseases (PROTECT-CAD trial).

Authors:  Hung-Fat Tse; Sukumaran Thambar; Yok-Lam Kwong; Philip Rowlings; Greg Bellamy; Jane McCrohon; Paul Thomas; Bruce Bastian; John K F Chan; Gladys Lo; Chi-Lai Ho; Wing-Sze Chan; Raymond Y Kwong; Anthony Parker; Thomas H Hauser; Jenny Chan; Daniel Y T Fong; Chu-Pak Lau
Journal:  Eur Heart J       Date:  2007-11-05       Impact factor: 29.983

9.  Development of bioactive peptide amphiphiles for therapeutic cell delivery.

Authors:  Matthew J Webber; Jörn Tongers; Marie-Ange Renault; Jerome G Roncalli; Douglas W Losordo; Samuel I Stupp
Journal:  Acta Biomater       Date:  2009-07-25       Impact factor: 8.947

10.  Mesenchymal stem cells from ischemic heart disease patients improve left ventricular function after acute myocardial infarction.

Authors:  Robert W Grauss; Elizabeth M Winter; John van Tuyn; Daniël A Pijnappels; Rebecca Vicente Steijn; Bianca Hogers; Rob J van der Geest; Antoine A F de Vries; Paul Steendijk; Arnoud van der Laarse; Adriana C Gittenberger-de Groot; Martin J Schalij; Douwe E Atsma
Journal:  Am J Physiol Heart Circ Physiol       Date:  2007-07-20       Impact factor: 4.733

View more
  8 in total

1.  Leptin signaling is required for augmented therapeutic properties of mesenchymal stem cells conferred by hypoxia preconditioning.

Authors:  Xinyang Hu; Rongrong Wu; Zhi Jiang; Lihan Wang; Panpan Chen; Ling Zhang; Lu Yang; Yan Wu; Han Chen; Huiqiang Chen; Yinchuan Xu; Yu Zhou; Xin Huang; Keith A Webster; Hong Yu; Jian'an Wang
Journal:  Stem Cells       Date:  2014-10       Impact factor: 6.277

2.  Human Umbilical Cord-Derived Mesenchymal Stromal Cells Improve Left Ventricular Function, Perfusion, and Remodeling in a Porcine Model of Chronic Myocardial Ischemia.

Authors:  Chuan-Bin Liu; He Huang; Ping Sun; Shi-Ze Ma; An-Heng Liu; Jian Xue; Jin-Hui Fu; Yu-Qian Liang; Bing Liu; Dong-Ying Wu; Shuang-Hong Lü; Xiao-Zhong Zhang
Journal:  Stem Cells Transl Med       Date:  2016-06-22       Impact factor: 6.940

3.  Vascular endothelial growth factor-delivery systems for cardiac repair: an overview.

Authors:  Teresa Simón-Yarza; Fabio R Formiga; Esther Tamayo; Beatriz Pelacho; Felipe Prosper; María J Blanco-Prieto
Journal:  Theranostics       Date:  2012-06-04       Impact factor: 11.556

4.  Extracellular high mobility group box 1 plays a role in the effect of bone marrow mononuclear cell transplantation for heart failure.

Authors:  Masahiro Kaneko; Yasunori Shintani; Takuya Narita; Chiho Ikebe; Nobuko Tano; Kenichi Yamahara; Satsuki Fukushima; Steven R Coppen; Ken Suzuki
Journal:  PLoS One       Date:  2013-10-18       Impact factor: 3.240

Review 5.  Assessment of stem cell carriers for tendon tissue engineering in pre-clinical models.

Authors:  Sunny Akogwu Abbah; Kyriakos Spanoudes; Timothy O'Brien; Abhay Pandit; Dimitrios I Zeugolis
Journal:  Stem Cell Res Ther       Date:  2014       Impact factor: 6.832

6.  Intrapericardial administration of mesenchymal stem cells in a large animal model: a bio-distribution analysis.

Authors:  Rebeca Blázquez; Francisco Miguel Sánchez-Margallo; Verónica Crisóstomo; Claudia Báez; Juan Maestre; Mónica García-Lindo; Alejandra Usón; Verónica Álvarez; Javier G Casado
Journal:  PLoS One       Date:  2015-03-27       Impact factor: 3.240

7.  Intrapericardial Delivery of Cardiosphere-Derived Cells: An Immunological Study in a Clinically Relevant Large Animal Model.

Authors:  Rebeca Blázquez; Francisco Miguel Sánchez-Margallo; Verónica Crisóstomo; Claudia Báez; Juan Maestre; Verónica Álvarez; Javier G Casado
Journal:  PLoS One       Date:  2016-02-11       Impact factor: 3.240

Review 8.  Optical fluorescence imaging with shortwave infrared light emitter nanomaterials for in vivo cell tracking in regenerative medicine.

Authors:  Leyla Fath-Bayati; Mohammad Vasei; Ehsan Sharif-Paghaleh
Journal:  J Cell Mol Med       Date:  2019-09-27       Impact factor: 5.310

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.